Gastrointestinal Stromal Tumor (GIST)

**Adult trials (Ages 18 and older)**

- **Interventional trials**
  - All Mutation Types (KIT, PDGFRA D842V, Wild)
    - 2nd Line Only
    - 3rd or 4th Line
    - 4th Line
      - IRB #19262
        A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
      - IRB #20580
        Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
      - IRB #17155
        A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies
  - KIT and PDGFRA (D842V) Mutations
    - At least 1 prior therapy
  - PDGFRA D842V Only
    - 2nd or 3rd Line
      - IRB #21229
        Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor

**CROSS-DISEASE TRIALS:**

- IRB# 19992 EAY131 (MATCH)
- IRB# S1609 (DART)

http://www.ohsu.edu/research/rga/so/knight.php

3/9/20